Business Wire

High-Quality Healthcare, Education Systems Highlighted in China's Two Sessions

Share

Building Healthy China and a high-quality education system are both important content in the draft outline of the 14th Five-Year Plan (2021-2025) for national economic and social development and the long-range objectives through the year 2035, which will be reviewed by lawmakers at the ongoing National People's Congress (NPC) session.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210306005020/en/

On the second day of this year's annual session of the NPC, China's national legislature, President Xi Jinping joined a group meeting with national political advisors from the education, medical and health sectors.

He attended joint group meetings with national political advisors from various sectors during the Two Sessions eight times from 2013 to 2020, hearing their comments and suggestions.

Ensuring people's health

Talking about work in medical and health areas, Xi reiterated holding people's health as a strategic priority, calling for more efforts in accelerating the implementation of the Healthy China initiative.

He also mentioned the experience gained from fighting against COVID-19 and said that facts have proven once again that prevention is the most cost-effective and effective health strategy.

Improving disease prevention and control system, developing a strong public health system, and stepping up healthcare system reforms are highlighted by Xi.

The country's public health protection network should be fortified, and efforts should be made to promote the high-quality development of public hospitals, he said, demanding comprehensive health care for the people at all stages of life.

From 2016 to 2020, the government arranged 141.5 billion yuan, up 23 percent since the 12th FYP period (2011-2015), from the central budget to invest in more than 8,000 public health projects such as the construction of disease control and prevention centers.

Meanwhile, hailing medical workers as the guardians of people's lives and health, Xi stressed strengthening protection and care for medical workers.

Since the virus outbreak, Xi has held multiple meetings, delivered important speeches, and made instructions to express the Communist Party of China (CPC) Central Committee's care for medical workers battling the epidemic at the frontline, especially in Hubei and its capital city Wuhan.

Building high-quality education system

As for work in education, Xi noted the need to comprehensively promote the reform of education methods, school-running mode, and management systems to further promote the construction of a high-quality education system.

According to the draft outline of the 14th Five-Year Plan, the education level of the entire population will be continuously improved, while the multi-tiered social security system and health system will be further enhanced.

The president also highlighted the role of teachers, calling them the backbone of education and saying that high-quality teachers make for high-quality education.

He also extended festive greetings and best wishes to the country's women of all ethnic groups and from all walks of life ahead of International Women's Day, which falls on March 8.

On all fronts, such as the decisive victory in building a moderately prosperous society in all respects, the decisive fight against poverty, and the COVID-19 pandemic, women have fought bravely and tenaciously, fully demonstrating the grace of women in the new era, said Xi.

https://news.cgtn.com/news/2021-03-06/Xi-meets-political-advisors-joins-discussions-at-annual-session-YpsWeY0u9q/index.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mandate of BaFin’s special commissioner at flatexDEGIRO terminated18.10.2024 18:25:00 EEST | Press release

Mandate of BaFin’s special commissioner at flatexDEGIRO terminated The mandate of the BaFin’s special commissioner at flatexDEGIRO Bank AG (the “Company”) was terminated on September 30, 2024, following the successful elimination of the serious deficiencies identified in the 2022 special audit by the Company and a positive review by the special commissioner. flatexDEGIRO AG made this announcement on October 18, 2024, following a corresponding decision by the German Federal Financial Supervisory Authority (BaFin). Oliver Behrens, CEO of flatexDEGIRO, said: “We have realigned and sustainably strengthened our organizational structures and processes in constructive cooperation with BaFin and the special commissioner. We are thereby closing a regulatory chapter and again increase our focus on our customers and important growth projects. My special thanks go to all employees who, under the leadership of Steffen Jentsch, member of the bank's management board, have made it possible to reach th

Biological Lattice Industries (BLI) Secures $1.8 Million Pre-Seed Funding Led by Uni.Fund to Democratize Biofabrication18.10.2024 17:00:00 EEST | Press release

Biological Lattice Industries Corp. (BLI), a leading innovator in biofabrication and life sciences R&D, today announced the successful closing of a $1.8 million pre-seed investment round led by Greek venture capital firm Uni.Fund. In conjunction with this funding announcement , BLI is introducing its first all-in-one solution for biofabrication: BioLoom™, BLI's advanced multi-tool 3D bioprinter and Loominus Studio™, its unified software platform designed to revolutionize biofabrication workflows. BLI, a US startup with R&D operations in Greece, aims to radically simplify biofabrication for the global R&D community by providing intelligent, automated tools that streamline the design, fabrication, and testing of biomaterials. Biomaterials are critical for a wide array of biological applications. The applications range from advanced 3D cell culture systems for human biology emulation to the next-generation of resorbable medical devices and drug delivery systems for tissue trauma repair. “

Gurobi Brings Decision Intelligence Summit to Amsterdam18.10.2024 16:00:00 EEST | Press release

Gurobi Optimization, LLC, the leader in decision intelligence technology, is set to host the first annual EMEAI Decision Intelligence Summit (“Gurobi Summit”) at Amsterdam’s Capital C on November 5-6, 2024. Following the success of last month’s inaugural summit for the Americas in Las Vegas, the EMEAI Summit will bring together operations researchers, data scientists, and business leaders from across the region to explore the latest advancements in mathematical optimization and decision intelligence. The Gurobi Summit will feature special presentations from companies such as Accenture and ICRON. Several of the company’s partners—including Decide4AI, Decision Labs, LTPLabs, and ORMAE—will also be present to showcase their solutions and insights. The two-day event will be packed with informative presentations, exciting customer case studies, and interactive learning opportunities. Day 1 will feature keynotes, technical presentations, and panel discussions. Day 2 will be dedicated to hand

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting18.10.2024 15:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania. Abstract A1187 — “Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy” will be presented as an oral presentation on Sunday, October 20, during the “Best Abstract” session, which runs from 8:00-11:00 a.m. ET, as well as the Education session which runs on Monday, October 21, from 1:30-2:30 p.m. ET. Abstract A2074 — “A Phase 3, Single-Arm Study of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor For Treatment of Acute Pain From Surgical and Non-surgical Conditions” will be present

SLB Announces Third-Quarter 2024 Results18.10.2024 13:50:00 EEST | Press release

SLB (NYSE: SLB) today announced results for the third quarter of 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241016795721/en/ The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2024Jun. 30, 2024Sept. 30, 2023SequentialYear-on-yearRevenue $9,159 $9,139 $8,310 - 10% Income before taxes - GAAP basis $1,507 $1,421 $1,395 6% 8% Income before taxes margin - GAAP basis 16.5% 15.5% 16.8% 91 bps -33 bps Net income attributable to SLB - GAAP basis $1,186 $1,112 $1,123 7% 6% Diluted EPS - GAAP basis $0.83 $0.77 $0.78 8% 6% Adjusted EBITDA* $2,343 $2,288 $2,081 2% 13% Adjusted EBITDA margin* 25.6% 25.0% 25.0% 55 bps 54 bps Pretax segment operating income* $1,902 $1,854 $1,683 3% 13% Pretax segment operating margin* 20.8% 20.3% 20.3% 48 bps 51 bps Net income attributable to SLB, excluding charges & cr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye